Filing Flows › Nurix Therapeutics (NRIX) › R&D spending
Nurix Therapeutics (NRIX) R&D spending by quarter
Nurix Therapeutics' R&D spending was $79.3M in Q3 FY26 (third quarter fiscal 2026), -10% from Q2 FY26. Over the last 7 quarters it ranged from $67.2M (Q4 FY24) to $87.7M (Q2 FY26).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 FY26 | $79.3M | -10% | -8% |
| Q2 FY26 | $87.7M | +4% | +12% |
| Q1 FY26 | $84.1M | +1% | — |
| Q4 FY25 | $83.0M | -4% | +24% |
| Q3 FY25 | $86.1M | +10% | — |
| Q2 FY25 | $78.1M | +16% | — |
| Q4 FY24 | $67.2M | — | — |
Q3 FY26 at a glance
Nurix Therapeutics, Q3 FY26: revenue $673M (85× year over year), operating margin 83.1%, net earnings $550M, operating cash flow $616M. The chart follows the revenue to costs, profit and cash.
Questions
What is Nurix Therapeutics' R&D spending?
Nurix Therapeutics' R&D spending was $79.3M in Q3 FY26 (third quarter fiscal 2026), -10% from Q2 FY26.
How has Nurix Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $67.2M (Q4 FY24) to $87.7M (Q2 FY26).